Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant

BACKGROUND: Rolapitant, a long-acting neurokinin (NK)(1) receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK(1) RAs, rolapitant does not inhibit or induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbour, S., Smit, T., Wang, X., Powers, D., Arora, S., Kansra, V., Aapro, M., Herrstedt, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452074/
https://www.ncbi.nlm.nih.gov/pubmed/28327932
http://dx.doi.org/10.1093/annonc/mdx073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452074/
https://www.ncbi.nlm.nih.gov/pubmed/28327932
http://dx.doi.org/10.1093/annonc/mdx073

Ejemplares similares